Novo's preprint covers 10,052 trial patients and ties semaglutide to organ ages one to four years younger, but none of it is peer reviewed yet.
Recap by typeshit. Full story at Medical Daily.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Doctors describe a rare esophageal perforation in a patient on semaglutide, a condition that can be deadly when diagnosis comes late.
Copenhagen researchers gave 108 adults with alcohol use disorder and obesity weekly shots or placebo alongside CBT, and blood tests backed up the drop.
Loading…